Shares of Teleflex Incorporated (NYSE:TFX – Get Rating) have earned an average rating of “Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $397.08.
Several research analysts have issued reports on TFX shares. Morgan Stanley dropped their price objective on Teleflex from $383.00 to $378.00 and set an “equal weight” rating for the company in a research note on Friday, February 25th. Raymond James dropped their price objective on Teleflex from $391.00 to $370.00 and set an “outperform” rating for the company in a research note on Wednesday, February 23rd. StockNews.com assumed coverage on Teleflex in a research note on Thursday, March 31st. They set a “buy” rating for the company. Piper Sandler raised their target price on Teleflex from $320.00 to $335.00 in a research note on Thursday, February 24th. Finally, TheStreet upgraded Teleflex from a “c+” rating to a “b-” rating in a research note on Wednesday, April 20th.
A number of institutional investors have recently bought and sold shares of TFX. HighTower Advisors LLC boosted its holdings in Teleflex by 0.8% during the third quarter. HighTower Advisors LLC now owns 4,652 shares of the medical technology company’s stock worth $1,759,000 after buying an additional 36 shares during the last quarter. Veritable L.P. boosted its holdings in Teleflex by 4.9% during the third quarter. Veritable L.P. now owns 793 shares of the medical technology company’s stock worth $299,000 after buying an additional 37 shares during the last quarter. Avalon Investment & Advisory boosted its holdings in Teleflex by 1.6% during the third quarter. Avalon Investment & Advisory now owns 2,661 shares of the medical technology company’s stock worth $1,002,000 after buying an additional 41 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Teleflex by 0.7% during the 3rd quarter. Mutual of America Capital Management LLC now owns 6,149 shares of the medical technology company’s stock valued at $2,315,000 after purchasing an additional 42 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teleflex by 62.9% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 114 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 44 shares in the last quarter. Institutional investors and hedge funds own 91.86% of the company’s stock.
Teleflex (NYSE:TFX – Get Rating) last issued its earnings results on Thursday, February 24th. The medical technology company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.53 by $0.07. The firm had revenue of $761.90 million during the quarter, compared to analysts’ expectations of $749.60 million. Teleflex had a return on equity of 17.74% and a net margin of 17.28%. Teleflex’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period last year, the business earned $3.25 earnings per share. Equities research analysts anticipate that Teleflex will post 14 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 15th. Investors of record on Monday, March 7th were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.42%. The ex-dividend date was Friday, March 4th. Teleflex’s dividend payout ratio is 13.28%.
Teleflex Company Profile (Get Rating)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
- Get a free copy of the StockNews.com research report on Teleflex (TFX)
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.